A Comprehensive Review on Treatment Strategies of Tay Sachs Disease

Tay-Sachs disease is a genetic disorder impacting the central nervous system due to HEXA enzyme deficiency, resulting in GM2 ganglioside accumulation and progressive neurological decline. Initially documented by Waren Tay and Bernard Sachs in Ashkenazi Jewish populations, the disease exhibits three types: infantile, juvenile, and late-onset, each differing in symptom onset and progression. Current therapies are primarily supportive, focusing on symptom management, with ongoing research exploring various treatment strategies. Enzyme Replacement Therapy (ERT) aims to replace the non-functional HEXA enzyme, though challenges exist in crossing the blood-brain barrier. Substrate Reduction Therapy (SRT) seeks to inhibit the synthesis of GM2 gangliosides, with compounds like miglustat showing potential but limited clinical success. Gene therapy, which introduces a functional HEXA gene, has shown promise in animal studies, while pharmacological chaperones aim to stabilize misfolded enzymes and increase their activity. Despite the constraints of current treatments, research developments in these areas offer hope for improving outcomes for individuals affected by Tay-Sachs disease, emphasizing the need for continued investigation to enhance therapy efficacy and patient quality of life. Advances in alternative strategies, such as gene therapy and pharmacological agents, could play a critical role in managing this rare condition.